Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma

Table 4 Univariate and multivariate analyses of risk factors for progression-free survival

Factors	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Sex
Male/female	1.145	0.692-49	0.599
Age (years)	1.007	0.987-1.027	0.495
ECOG PS
0/1	1.246	0.781-1.988	0.357
Child-Pugh class
A/B	1.301	0.881-1.921	0.185
AFP (ng/mL)
≤ 400/> 400	1.215	0.821-1.798	0.329
Number of tumors
≤ 3/> 3	1.276	0.857-1.900	0.229
Largest tumor size (mm)	1.006	0.998-1.013	0.139
PVTT
No/yes	1.590	1.073-2.358	0.021	1.670	1.120-2.491	0.012
Hepatic vein invasion
No/yes	1.621	1.012-2.596	0.044	1.807	1.105-2.956	0.018
Extrahepatic metastasis
No/yes	1.778	1.038-3.044	0.036	1.554	0.900-2.686	0.114
Treatment option
D-TACE-P-L/C-TACE-P-L	1.422	0.961-2.104	0.078	1.536	1.028-2.293	0.036

C-TACE-P-L: Conventional transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; D-TACE-P-L: Drug-eluting beads transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; ECOG PS: Eastern Cooperative Oncology Group Performance Status; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; HR: Hazard ratio; CI: Confidence interval.